H.C. Wainwright Reiterates Buy Rating on Aurinia Pharma (AUPH) as EU approval of LUPKYNIS triggers a $30M milestone payment
Tweet Send to a Friend
H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $26.00 price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) as EU ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
